HC Wainwright Reiterates “Buy” Rating for XOMA (NASDAQ:XOMA)

XOMA (NASDAQ:XOMA)‘s stock had its “buy” rating reissued by HC Wainwright in a note issued to investors on Tuesday,Benzinga reports. They presently have a $123.00 target price on the biotechnology company’s stock. HC Wainwright’s price objective indicates a potential upside of 377.86% from the company’s current price.

Separately, StockNews.com lowered shares of XOMA from a “hold” rating to a “sell” rating in a research report on Friday, December 27th.

XOMA Stock Performance

XOMA stock opened at $25.74 on Tuesday. The firm’s 50 day simple moving average is $29.20 and its 200 day simple moving average is $27.94. The firm has a market capitalization of $303.29 million, a PE ratio of -7.40 and a beta of 0.92. The company has a current ratio of 7.52, a quick ratio of 7.52 and a debt-to-equity ratio of 1.28. XOMA has a 1-year low of $18.57 and a 1-year high of $35.00.

Insider Transactions at XOMA

In related news, CEO Owen Hughes sold 21,881 shares of XOMA stock in a transaction that occurred on Wednesday, November 13th. The stock was sold at an average price of $29.95, for a total transaction of $655,335.95. Following the sale, the chief executive officer now directly owns 34,979 shares in the company, valued at $1,047,621.05. The trade was a 38.48 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 7.20% of the company’s stock.

Institutional Investors Weigh In On XOMA

Several hedge funds have recently added to or reduced their stakes in XOMA. BNP Paribas Financial Markets increased its holdings in XOMA by 95.0% in the 3rd quarter. BNP Paribas Financial Markets now owns 1,632 shares of the biotechnology company’s stock worth $43,000 after buying an additional 795 shares in the last quarter. Geode Capital Management LLC raised its stake in XOMA by 0.6% during the 3rd quarter. Geode Capital Management LLC now owns 182,741 shares of the biotechnology company’s stock valued at $4,840,000 after purchasing an additional 1,138 shares during the period. Rhumbline Advisers raised its position in shares of XOMA by 16.0% during the second quarter. Rhumbline Advisers now owns 9,695 shares of the biotechnology company’s stock valued at $230,000 after buying an additional 1,334 shares during the last quarter. State Street Corp boosted its position in shares of XOMA by 1.2% during the third quarter. State Street Corp now owns 142,857 shares of the biotechnology company’s stock worth $3,783,000 after acquiring an additional 1,754 shares during the last quarter. Finally, Bank of New York Mellon Corp grew its holdings in XOMA by 3.2% during the 2nd quarter. Bank of New York Mellon Corp now owns 62,656 shares of the biotechnology company’s stock valued at $1,484,000 after buying an additional 1,968 shares in the last quarter. 95.92% of the stock is owned by institutional investors.

About XOMA

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.